Novo Nordisk Shares Plunge on Insulin's FDA Failure

Feb. 11 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk shares have fallen the most in a decade as the company's new insulin drug Tresiba has failed to win FDA approval in the United States. She speaks on Bloomberg Television's "The Pulse."
Making Classic Shoes for Less
40:42 - Mar. 02 -- Lane Gerson discusses his growing show company, "Jack Erwin," with Pimm Fox. They speak on "Taking Stock." (Source: Bloomberg)
  • Business Booms for Snow Removal Company
  • Nasdaq Tops 5,000 for First Time in 15 Years
  • Was Lumber Liquidators Legally Compliant?